Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates 88.9% tumor inhibition using a catalytic nanoplatform, highlighting a synergistic strategy for multimodal cancer therapy.
This work introduces the rational design of a hierarchically structured, multi-enzyme integrated therapeutic platform, referred to as HCuS/Ag/Pt/ICG/DOX (CAPID). The platform is constructed by depositing dual-enzyme-active Ag/Pt on copper sulfide nanoparticles (CuS NPs) to remodel the tumor microenvironment (TME), followed by loading indocyanine green (ICG) as a near-infrared (NIR) fluorophore and doxorubicin (DOX) as a chemotherapeutic payload. The CAPID platform utilizes catalase to decompose H₂O₂ into oxygen (O₂), which synergizes with endogenous H₂O₂ to initiate a Fenton-like reaction, generating cytotoxic hydroxyl radicals (·OH). The redox cycling between Cu² ⁺ ions and intracellular thiols depletes GSH, amplifying oxidative stress cascades. NIR irradiation achieved 88.9 % tumor inhibition via spatiotemporal tri-therapy (chemo/PDT/PTT) synergy, thereby addressing the limitations of monotherapy through nanoplatform engineering.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: